Utilizing RNAscope in the clinic to handle complex analysis.
Thursday, June 23 at 11:00am EST
RNAscope is rapidly becoming a solution for understanding complex biomarker challenges. The benefits and awareness of image analysis in the space of pathology have been widely discussed and rapidly growing. From alleviating staffing shortages to accelerating turnaround times, and from increased consistency and accuracy to innovative teaching tools. For many researchers, moving into very complex analysis is nearly impossible due to the output data requirements. Image analysis and machine learning solutions allow efficient, concise data from RNAscope to be generated for pathologists to verify. The large data sets and complex read outs are minimized with a combined solution while obtaining critical information around your target. We will discuss specific examples of how RNAscope + IA solves development problems.
Mike Kagey, PhD, Senior Director of Translational Medicine at Leap Therapeutics
Mike Kagey is a translational biologist with over 15 years of experience in epigenetics and cell signaling. Mike is currently a Senior Director of Translational Medicine at Leap Therapeutics. There, he leads the biomarker and CDx program for DKN-01, a therapeutic antibody targeting the Wnt signaling modulator DKK1, which is currently in multiple phase 2 oncology trials. Previously, Mike led discovery and biomarker efforts at Tensha Therapeutics (acquired by Roche). Mike was a postdoctoral fellow at the Whitehead Institute for Biomedical Research in the laboratory of Richard Young, where he worked on epigenetics and gene regulation in embryonic stem cells and cancer cells.
Xiaoshan Wang, MS, MBA, Senior Product Manager at Advanced Cell Diagnostics
Xiaoshan Wang is Sr Product Manager at Advanced Cell Diagnostics, a Bio-Techne Company in Newark California, where he focuses on RNAscope™ clinical applications. With over 10 years in the biotechnology/clinical diagnostics field, Xiaoshan received his Master of Science degree in biomedical sciences from Virginia Tech and his M.B.A. from University of California, Berkeley Haas School of Business.
Meredith James, HT, PMP, Chief Commercial Officer at Flagship Biosciences
Meredith James, HT, PMP, is the Chief Commercial Officer at Flagship Biosciences, Inc., the leader in data-centric pathology services and tissue analysis. Founded in 2009 and headquartered in Broomfield, Colorado, Flagship is revolutionizing tissue analysis to improve drug development and diagnostics using the power of AI. The company’s patented technology and proprietary workflow significantly improve on the data and interpretation from traditional pathology methods. It eliminates the variability associated with typical assessments and brings new insights to tissue analysis from its CLIA certified and CAP accredited lab. With expert scientific consultation for every client, Flagship’s team interprets results, contextualizes tissue biology, and identifies the best course for success.
Since joining Flagship in July of 2019, Ms. James has held positions of leadership in both operations and sales and marketing, supporting the continued delivery of the highest quality data to Flagship’s clients and bringing Flagship’s unique capabilities to market. With a 20+ year career in the pharmaceutical industry spanning laboratory operations and clinical program and project management, Ms. James previously led translational programs at Precision for Medicine. She also held leadership positions at PPD Laboratories and Quintiles (now part of IQVIA) where she helped to develop, manage, and organize processes and vendor relationships. Ms. James’ additional years in laboratory, IT, and account and project management make her an incredible asset to Flagship. Ms. James received her BS degree in biology from Virginia Polytechnic Institute and State University, and her MS/MBA (matriculated); BS; BA in Biotechnology from The Johns Hopkins University.
Roberto Gianani, MD, FCAP, Medical Director and Chief Medical Officer at Flagship Biosciences
Dr. Roberto Gianani, Chief Medical Officer at Flagship Biosciences, Inc., is a practicing pathologist who is board certified in anatomic pathology, clinical pathology, and pediatric pathology. He is also fellowship-trained in surgical pathology and transfusion medicine and has a specialization certification in endocrinology. His research interests include the pathology of immune-oncology and image analysis. Roberto’s professional experience includes several years as an academic pathologist at the University of Colorado and numerous laboratory directorships. He has published extensively in the field on immunology, pathology, and autoimmunity, and he holds patent number US005407802A, entitled: Method of accessing the risks of developing Type 1 diabetes. Roberto received his medical degree from the Sapienza University of Rome.